All In Biotech

Drug Trial Radar · NCT05220072

Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156

An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of Carbon-14 BIA 28-6156 in Healthy Male Subjects

Last checked: Nov 20, 2026Latest source record: May 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Aug 28, 2021

Primary completion

Oct 16, 2021

Study completion Oct 16, 2021

Sponsor

Lead sponsor
Bial R&D Investments, S.A.Industry
Sponsor type
Industry
First posted
Feb 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 30 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is designed to determine the absorption, distribution, metabolism and elimination (ADME) of BIA 28-6156 in humans, further explore the PK of BIA 28-6156, evaluate the extent of distribution of total radioactivity into blood cells, provide additional safety and tolerability information and collect samples for metabolite profiling and structural identification.

Conditions

  • Parkinson Disease

Interventions

  • Carbon-14 BIA 28-6156Drug

    Carbon-14 BIA 28-6156 60 mg, containing NMT 3.7 MBq Carbon-14

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mass balance recovery of total radioactivity in all excreta (urine and faeces)Time frame: Urine: Day 1 through Day 11, Faeces: Day -1 through Day 11
  2. Collection of urine and faecal samples for total radioactivityTime frame: Urine and Faeces: Pre-dose until 288 hours post-dose
  3. Collection of plasma samples for metabolite profilingTime frame: Pre-dose until 240 hours post-dose
  4. Collection of plasma samples for structural identificationTime frame: Pre-dose until 240 hours post-dose
  5. Collection of whole blood samples for total radioactivityTime frame: Pre-dose until 240 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences

    Ruddington, Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.